Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy Number

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy Number / S. Pilotto, E. Bria, U. Peretti, F. Massari, M. Garassino, G. Pelosi, G. Tortora. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 8:12(2013), pp. e105-e106.